CD22 4AP

Drug Profile

CD22 4AP

Alternative Names: CD22-4AP; TRPH-222

Latest Information Update: 08 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Catalent Pharma Solutions
  • Developer Triphase Accelerator Corporation
  • Class Immunoconjugates
  • Mechanism of Action CD22 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical B cell lymphoma

Most Recent Events

  • 01 May 2017 Triphase Accelerator completes pre-IND and pre-CTA discussions with the United States Food and Drug Administration and Health Canada for the clinical development of CD22-4AP
  • 04 Oct 2016 Preclinical trials in Cancer in USA (unspecified route)
  • 04 Oct 2016 CD22 4AP licensed to Triphase Accelerator Corporation worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top